Navigation Links
Union Equity, Inc.'s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy

ORLANDO, Fla., June 13, 2012 /PRNewswire/ -- Union Equity Inc. (OTC: UNQT) is pleased to announce that its wholly owned subsidiary, Natural Product Laboratories LLC, has developed Allevium, a creme that contains natural ingredients and plant extracts, which aids in soothing the effects of chemotherapy treatment. The Allevium compound targets damaged and irritated skin and promotes soothing repair for affected areas.*

Each year, 10.9 million people worldwide are diagnosed with cancer and this incidence is rising. This increase reflects the world's growing population and the fact that people are living longer, according to the New Zealand Dermatological Society ( Chemotherapy and radiation treatment are in many cases crucial components to cancer management, a treatment that itself does not come without side effects, as doctors and patients alike will see an increasing incidence of, among other unwanted effects, cancer treatment related skin toxicity. Chemotherapy and radiation may cause skin irritations, such as redness, peeling, itching and dryness. The skin may look as if it is sunburned or tanned, and acne issues may present themselves.

Union Equity's subsidiary Natural Product Laboratories announces today that it is beginning its initial product distribution of three different versions of its Allevium product: Allevium Intense Repair Creme, Allevium Daily Moisture Creme and Allevium Solor Protection SPF 30. The Allevium line's target market is anyone who is looking to soothe the burns, breakouts and skin irritation suffered from chemotherapy and radiation therapy.

"As a mother who had to watch her daughter go through cancer treatments that ravaged her skin, I am proud to offer her and others a solution that will relieve them of their skin irritations," stated Pat Landers, Assistant Director of Operations for Natural Product Laboratories LLC. "I know the pain families feel standing by helplessly, watching their loved ones suffer. Our chemist and micro-biologist have developed a formulation that combines natural vitamins and plant extracts, along with other reparative ingredients, that soothe and nurture damaged skin from any cause, but in particular  whose skin damage is a result of cancer related skin toxicity."

* The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and this product is not intended to diagnose, treat, cure, or prevent any disease.

To learn more about Natural Product Laboratories, please call the toll free number: 888-522-2550

To learn more about Union Equity Inc., please visit:

Follow Union Equity, Inc. on Twitter:!/UNQT

About Natural Product Laboratories LLC:
The Natural Product Laboratories LLC (NPL) laboratory and production facility is located in Melbourne, Florida and is FDA regulated and certified as well as Green Seal approved to produce the highest quality skin-care, personal care, hair, pet, baby and sunscreen products. The Company specializes in formulizations of new product lines as well as reverse engineering existing products. The staff includes a licensed chemist and certified microbiologist, with over 25 years' combined experience. NPL's skilled production team and broad range of equipment allows them to accommodate almost any size order. Packaging capabilities include a wide range of sizes for both professional and retail use.

Safe Harbor Act:
This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

David Donlin
Cervelle Group


SOURCE Union Equity, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
2. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
3. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
4. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
5. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
6. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
7. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
8. AquaLiv Technologies, Inc. and Its Subsidiary, AquaLiv, Inc., Release Funding Updates
9. NASA develops super-black material that absorbs light across multiple wavelength bands
10. UCLA team develops highly efficient method for creating flexible, transparent electrodes
11. Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products
Post Your Comments:
(Date:10/13/2015)... PARK, N.J. and SAN DIEGO ... (BASF) and Mast Therapeutics, Inc. have agreed to collaborate ...  Currently, excipient-grade poloxamer 188 NF, marketed by BASF under ... used in a variety of pharmaceutical and biological applications, ... Poloxamer 188 is the starting material for Mast,s lead ...
(Date:10/13/2015)... , Oct. 13, 2015  Generex Biotechnology Corporation ( ... a non-binding Letter of Intent (LOI) with MediTemp Ltd. (MediTemp) ... a proprietary cooling technology designed to improve sperm quality in ... United States and three million men in ... 44 diagnosed as infertile.  For 42% of those men, the ...
(Date:10/13/2015)... ... , ... Proove Biosciences, a commercial and research leader ... Keck Medicine of the University of Southern California (USC) Pain Center to ... Research Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one ...
(Date:10/12/2015)... ... October 12, 2015 , ... Spirax Sarco, the leader in products ... CSM-C 600 compact clean steam generator . This unit is a skid ... of HTM2031, HTM2010, and EN285 standards. The CMS-C 600 generator can produce up ...
Breaking Biology Technology:
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
(Date:9/29/2015)... , Sept. 29, 2015 News ... productivity while also saving energy , Minimized design ... Low Power Active Mode and embedded Fujitsu PalmSecure authentication ... Fujitsu today shows that good things come ... refreshed models to its enterprise desktop and mobile portfolio. ...
(Date:9/28/2015)... , September 28, 2015 ... expected to reach USD 12.03 billion by 2020, growing ... Technological advancements such as Backside Illumination (BSI) technique to ... over the forecast period.      (Logo: ... of the chip to reduce loss and, thus, reduce ...
Breaking Biology News(10 mins):